Press releases

  • 2017-08-01 08:00

    Bio-Works strengthens the management with Mats Johnson as new CEO

    Mats Johnson will from today, August 1 2017, take over the responsibility as CEO for Bio-Works Technologies AB (”The Company”). At the same time Thomas Pollare will take over Mats Johnson´s position as chairman of the board and Kris Fain, who has been CEO to this time, will leave the company. The purpose with these changes is to further strengthen the focus within the life science segment where The Company now is established as a supplier of high performance products with larger volume of repeat orders from leading global companies. This change is also part of the preparation of the IPO planned for the end of 2017.

    “2017 has so far been a very good year for Bio-Works with growing sales to customers in Europe and a new strategic investor who will open up the very fast growing market for biosimilar production in South Korea for us. I look very much forward to accelerate the growth of Bio-Works in the life science segment. It is clear that the present growth of Bio-Works comes from sales of our high performance products to key customers in the life science industry. ”, says Mats Johnson, new CEO for Bio-Works.

    Mats Johnson has previously been CEO of SweTree Technologies, where he served for over 10 years and took them from early start-up to profitability. Prior to that, he served during 18 years in various commercial and strategic leadership roles with Pharmacia Biotech and other predecessors to GE Life Sciences. He has a good insight and understanding of Bio-Works’ business, its product mix and customer need.
    “The board wants with these changes strengthen The Company for our important strategic steps the next coming years with the focus on accelerated sales and the planned IPO at the end of 2017. At the same time we thank Kris for his diligent work in changing and building The Company during his period as CEO”, says Thomas Pollare, new chairman of the board.

    For more information, please contact
    Mats Johnson, VD, Bio-Works Technologies AB
    Mobile: +46 705 165337
    E-mail: mats.johnson@bio-works.com

    About Bio-Works
    Bio-Works, founded 2006 and based in Uppsala, Sweden, designs, develops, manufactures and supplies innovative agarose separation products for the Life Science and Food & Beverage industries. The Bio-Works team has extensive experience in the biotech industry and expertise in developing high performance separation and chromatography media. Our knowledge and capabilities in the life science and food & beverage areas have resulted in a strong product portfolio serving high performance research applications, as well as commercial production requiring high purity and high yield. Our strategic focus is to grow rapidly and profitably in the space of “separation of biomolecules”, notably proteins and peptides, where there are large addressable markets and healthy growth.

    info
  • 2016-06-01 04:15

    May 25, 2016 Bio-Works Technologies AB New Share Issue Fully Subscribed

    Bio-Works Technologies AB is pleased to announce that its recent new share issue has been fully subscribed. Vator Securities in Stockholm advised and managed the funding round.
    “We appreciate the renewed support of our existing investors and welcome new investors. This capital funding round will allow the Bio-Works team to accelerate commercialization and sales growth of its core agarose separation media products in Life Science and Food & Beverage sectors. Simply put, we will focus on doing more of what works”, says Mikael Gordon, chairman of the board Bio-Works. “We have had very good product performance with excellent customer feed-back in target markets with high growth potential, and with the recent Vinnova grant for the development of our bio-based emulsion production process we are in a strong position to grow rapidly” add Kris Fain, CEO.

    For more information, please contact

    Kris Fain, CEO Bio-Works Technologies AB
    Mobile: +46 735 18 90 80
    E-mail: kris.fain@bio-works.net

    info
  • 2016-05-17 15:08

    May 17, 2016 Bio-Works Technologies AB are proud to announce that it has been awarded a Vinnova grant of over 1.5 MSEK for production process innovation

    Bio-Works Technologies AB has  been awarded  over 1.5M SEK by Vinnova, the Swedish grant authority, to develop an improved and environmentally sustainable process for the production of Bio-Works WorkBeads brand agarose separation media used in the purification of high value of proteins in the life science and food & beverage industries.  
    This process development project will allow for increased production capacity of the Bio-Works factory in Uppsala while improving the environmental profile of production through a bio-based emulsification method using vegetable oils.  This new bio-based emulsification process will also allow for greater innovation within the Bio-Works portfolio of agarose media products to better serve life science and food & beverage segments where the need for high quality and high yield protein separation is paramount.
    ”We are very pleased that Vinnova rewarded our innovative and environmentally sustainable approach to improving a key part our manufacturing process.  Our process development team has done excellent work in mapping a process that will allow us to grow quickly while reducing environmental impact and creating an improved factory work environment.” commented Kris Fain, CEO of Bio-Works.
    Bio-Works will continue to drive innovation in biomolecule separation technology serving the biopharma, biotechnology and food & beverage industries.

    For more information, please contact
    Kris Fain, CEO Bio-Works Technologies AB
    Mobile +46 735 18 90 80
    e-mail kris.fain@bio-works.net

    Link to Vinnova announcement:  


    Vinnova and Bio-Works Sweden AB - Biobaserade emulsioner

    info
  • 2016-03-09 10:54

    March 9, 2016 - Bio-Works Technologies AB being granted patents for a novel production method of agarose separation gel

    The European Patent Office has informed Bio-Works that they intend to grant the patent for the innovative production method of its agarose separation gel, marketed under the brand WorkBeads. This follows upon the US Patent Office having granted the patent in July 2015 (US Patent No. 9,045,566 B2).  The Press release is available below in English and Swedish.

    Agarose separation media is fundamental to the purification of high value proteins in life science and food & beverage industries. The key feature of the agarose materials are their protein-friendly surface properties. Agarose technology has for many years been an essential tool for the purification of proteins in the discovery and production of many bio-pharmaceutical drugs. It is now being used increasingly in dairy, food and beverage ingredient purification due to high yield at high purity levels.

    Bio-Works’ new patented process enables the more efficient manufacturing of its WorkBeads brand agarose separation beads. The process dramatically reduces the length of production time to produce high quality and high performance agarose beads. “This significant increase in manufacturing efficiency is the result of Bio-Works’ investment in research, product and process development”, commented Kris Fain, CEO of Bio-Works.

    Bio-Works will continue to drive innovation in biomolecule separation technology serving biopharma, biotechnology and food & beverage processors.
    Kris Fain will present the company and its revolutionary technology at the Vator Securities Unicorn Summit, held at IVA, Grev Turegatan 16, Stockholm, today, March 9, at 7pm.

    For more information, please contact
    Kris Fain, CEO Bio-Works Technologies AB
    Mobile: +46 735 18 90 80
    E-mail: kris.fain@bio-works.net

    Bio-Works Press Release Patent 9 mars SWE 20160309.pdf
    Bio-Works Press Release Patent 9 March ENG 20160309.pdf

    info
  • 2016-02-17 16:12

    February 16 2016 - Bio-Works Technologies AB presents at Vator Securities Unicorn Summit in Stockholm, March 9 at 19.00

    Vator Securities Unicorn Summit är en kapitalmarknadsdag med några av de mest
    intressanta svenska Life Science-bolagen. Eventet anordnas den 9 mars 2016 på IVA i
    Stockholm, med start klockan 15:00.

    Bio-Works är ett av fem utvalda bolag som skall presenteras under eftermiddagen.
    Presentationen börjar klockan 19:00. Kris Fain, CEO ska bland annat tala om
    att bolaget haft sitt starkaste kvartal hittills och har en växande lista kvalificerade potentiella
    kunder. Bolaget är i en fas där fokus ligger på att göra mer av det som fungerar bäst för ett
    snabbare genomslag på marknaden. Målet är att bygga på framgångarna Bio-Works har haft
    med små och medelstora läkemedelsföretag samt livsmedelsproducenter (enzymer, mjölk
    och öl) i Europa och Nordamerika.

    Vator Securities har ända sedan starten 2009 framgångsrikt bistått bolag, entreprenörer
    och investerare inom Life Science-sektorn med finansiell rådgivning. Visionen är att leda
    arbetet med att skapa ett svenskt supercluster där kunniga investerare finner snabbt
    växande bolag med potential att bli nästa svenska Unicorn (bolag med över 1 miljard dollar
    i marknadsvärde) inom Life Science.

    För mer information, vänligen kontakta kris.fain@bio-works.net

    Bio-Works Vator release 170216.pdf

    Kris Fain
    CEO, Bio-Works Technologies AB

    info
  • 2016-02-01 09:47

    January 29, 2016 - Significant order of WorkBeads for purification of proteins from milk whey

    We are delighted to announce that Bio-Works received a significant order of WorkBeads. Our product will be used in a process for the isolation and purification of proteins from milk whey. This order is the result of our focus on dairy, a key element of our food  & beverage strategy.  We will continue to leverage our agarose separation expertise to serve customers in dairy and other food and beverage segments.  The order, worth approximately 735 000 SEK, was placed in December and  delivered in January.

    Kris Fain
    CEO

    info
  • 2015-12-10 12:26

    December 9, 2015 - Kris Fain as new CEO Bio-Works

    January 7, 2016 Kris Fain joins Bio-Works as Chief Executive Office based in Uppsala Sweden. In his role he will have overall accountability for developing the company further in the Life Sciences and Food & Beverage markets with a focused strategy building on the company’s experience over the last few years.

    Kris has executive international experience USA, Italy, France and Sweden where he had roles in sales, marketing and general management. He has had senior roles in Tetra Laval Group Sam MeadWestvaco Corporation and SPX Corporation, Flow Technology and Samsonite. Having worked for almost two decades with advanced technologies in the Food & Beverage industry, we believe Kris will bring significant customer and market knowledge from this industry to supplement the existing Life Science experience in Bio-Works. Further Kris has a graduate in International Relations from Brown University (RI-USA) and an MBA in International Management from Thunderbird (AZ-USA).  

    “I am extremely excited to have someone of Kris’s experience joining our team as CEO. He has tremendous experience in managing international businesses and in the Food & Beverage market. He brings strong leadership and I am confident that Kris will drive strong results as we now focus on building our market presence”.

    Mikael Gordon
    Chairman

    info
  • 2015-02-05 14:01

    February 5, 2015 - Development of business and commercial operations

    Bio-Works Technologies AB jointly with its subsidiary Bio-Works Sweden AB (Uppsala, Sweden)announces appointment of GH BioQuenta Consulting e.U/Dr. Gabriel Halát (Vienna, Austria) to develop business and commercial operations; East - Central Europe, South Eastern Europe, Eastern Europe, East Mediterranean, Middle East, Africa and South Africa.

    info
  • 2014-12-18 14:02

    December 18, 2014 - Bio-Works Technologies AB raises 30.3 million SEK in pre-IPO Investment Round

    Company announces that it has raised 30.3 million Swedish Krona in a successful pre-IPO investment round. The two times oversubscribed round will allow Bio-Works to continue expansion of the strong product portfolio and its facilities in Uppsala, Sweden.

    The investment enables Bio-Works to meet strong customer demand for its agarose bead products in the life science and food and beverage markets by increasing team of specialists in each area, plant and equipment as well as sales and marketing resources to drive Bio-Works’ expansion plan prior to a planned IPO in late 2016. Vator Securities was the financial advisor for the new share issue.

    info
  • 2013-10-01 13:03

    October 1, 2013

    Bio-Works starts deliver products manufactured in Uppsala after extensive efforts installation and validation of equipment etc.

    info
  • 2013-03-10 14:03

    March 10, 2013

    Bio-Works moves from plant in Bromma to new facilities for research, development and production in Uppsala Business Park in Fyrislund Uppsala. Company´s products are developed for Life scientists, Food & beverage producers and CleanTech industry.

    info
  • 2011-07-15 13:03

    July 15, 2011

    Bio-Works launches WorkBeads 40 Ni for capture of histidin containing proteins. Based on a Vinnova grant Bio-Works has developed a high capacity adsorbent for histidin containing proteins. To capture histidin contining proteins (His tagged) is common practice in proteomic research. With introduction of WorkBeads 40 Ni which has at least 30% more capacity than leading products on the market productivity in proteomic research will be further enhanced.

    info
  • 2011-06-26 13:04

    June 29, 2011

    Bio-Works a Supplier to Qiagen

    Bio-Works Co. Ltd is proud to announce that they have passed Qiagen’s rigid screening process for raw material suppliers and are now supplying WorkBeads 40 SEC for use as the core component in Qiagen’s manufacture of one of their key products.

    We are delighted that we have met the technical and delivery requirements of so prestigious a company and look forward to a long term partnership with Qiagen, a world leading biotech company.

    info